The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial

Qun Zhao, Changhong Lian, Zhibin Huo, Ming Li, Yang Liu, Liqiao Fan, Bibo Tan, Xuefeng Zhao, Zhidong Zhang, Dong Wang, Yu Liu, Honghai Guo, Peigang Yang, Yuan Tian, Yong Li, Qun Zhao, Changhong Lian, Zhibin Huo, Ming Li, Yang Liu, Liqiao Fan, Bibo Tan, Xuefeng Zhao, Zhidong Zhang, Dong Wang, Yu Liu, Honghai Guo, Peigang Yang, Yuan Tian, Yong Li

Abstract

Objectives: Exploring the efficacy and safety of perioperative chemotherapy on patients with AGC at different clinical and pathological stages.

Methods: A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin (XELOX, arm C) was initiated in T3/4, node + gastric cancer patients (unclear). Each patient received an 8-cycle chemotherapy (3 weeks for one cycle). Group arms B and C received two cycles preoperatively, and six cycles postoperatively. Primary endpoints were R0 resection rate and DFS, and secondary endpoints included OS, ORR, DCR, and safety. This study was registered on Clinicaltrials.gov. NCT01516944.

Results: A total of 749 patients were randomly assigned into groups A, B, and C. Group A received 1460 circles chemotherapy and group B received 1177 circles while group C received 1200 circles. R0 resection rates in the three groups were 81.7%, 88.7%, and 83.1%, respectively. The difference between groups A and B was considered to be statistically significant (P = .018), and no significant difference between groups B and C (P = .051). Hazard ratio were compared between groups B and C and DFS showed 0.72 (0.67-0.77 with 95% CI), Pnon-inferiority < .0001, Plog-rank = .064). The CI top limit actually lower than the estimated value of 1.38, which indicated noninferiority of SOX to XELOX.

Conclusions: Compared with PAC, perioperative chemotherapy showed a significant improvement in R0 resection rates and prognosis in AGC patients with higher safety rates. This study was powered to show superiority of perioperative over adjuvant SOX, and noninferiority of SOX to XELOX. Volume measurement, repeated laparoscopic exploration combined with exfoliative cytology can be used as a supplementary method in the clinical staging and efficacy evaluation of AGC.

Keywords: SOX; XELOX; gastric cancer; neoadjuvant chemotherapy; survival analysis.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Trial profile
FIGURE 2
FIGURE 2
The transition and time course of surgical exploration, peritoneal lavage cytology, and efficacy assessment
FIGURE 3
FIGURE 3
Laparoscopic exploration revealed the presence of peritoneal metastasis
FIGURE 4
FIGURE 4
Comparison of positive and negative survival rates of peritoneal lavage cytology
FIGURE 5
FIGURE 5
The IIIC staging patients were stratified according to the median volume of 62.5 cm3, and the overall survival of the two groups of patients was compared
FIGURE 6
FIGURE 6
Evaluation of the percentage change of primary gastric cancer volume in ROC curve analysis for the effectiveness of chemotherapy
FIGURE 7
FIGURE 7
Comparison of postoperative survival rate between chemotherapy‐effective group and chemotherapy‐ineffective group in the percentage change of volume change
FIGURE 8
FIGURE 8
Comparison of overall survival between the three groups
FIGURE 9
FIGURE 9
Comparison of disease‐free survival between the three groups
FIGURE 10
FIGURE 10
Forest plot graph of subgroup analysis (group B vs group C)

References

    1. International Agency for Research on Cancer (IARC) . GLOBOCAN 2018: estimated cancer incidence, mortality and prevalence worldwide in 2018; 2018.
    1. Yamashita K, Kurokawa Y, Yamamoto K, et al. Risk factors for poor compliance with adjuvant S‐1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24:2639‐2645.
    1. Bang Y‐J, Kim Y‐W, Yang H‐K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379:315‐321.
    1. Sasako M, Sakuramoto S, Katai H, et al. Five‐year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‐1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387‐4393.
    1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11‐20.
    1. Zhao Q, Li Y, Tian Y, et al. Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma. Hepatogastroenterology. 2013;60:638‐640.
    1. Zhao Q, Li Y, Huang J, et al. Short‐term curative effect of S‐1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study. Pharmazie. 2017;72:236‐240.
    1. Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24:478‐485.
    1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725‐730.
    1. Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28:1876‐1881.
    1. Palmela C, Velho S, Agostinho L, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer. J Gastric Cancer. 2017;17:74‐87.
    1. Ychou M, Boige V, Pignon J‐P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715‐1721.
    1. Xu W, Beeharry MK, Liu WT, Yan M, Zhu ZG. Preoperative chemotherapy for gastric cancer: personal interventions and precision medicine. Biomed Res Int. 2016;2016:3923585.
    1. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210‐5218.
    1. Koizumi W, Narahara H, Hara T, et al. S‐1 plus cisplatin versus S‐1 alone for first‐line treatment of advanced gastriccancer (SPIRITS trial): a phase Ⅲ trial. Lancet Oncol. 2008;9:215‐221.
    1. Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S‐1 as first‐line treatment for advanced gastric cancer (G‐SOX study). Ann Oncol. 2010;21:1001‐1005.
    1. Park I, Lee J‐L, Ryu M‐H, et al. Phase I/II and pharmacokinetic study of S‐1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2010;65:473‐480.
    1. Konishi S, Manaka D, Ikeda Y, et al. Phase II study of neoadjuvant chemotherapy with S‐1 plus oxaliplatin at a dose of 130 mg/m2 (nacG‐SOX130) in clinical(c)Stage III gastric cancer. Ann Oncol. 2019;30(Suppl 4):iv27‐iv28.
    1. Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329‐338.
    1. Thiels CA, Ikoma N, Fournier K, et al. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018;118:61‐67.
    1. Takahari D, Boku N, Mizusawa J, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan Clinical Oncology Group 9912. Oncologist. 2014;19:358‐366.
    1. Ichikawa W, Takahashi T, Suto K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer. 2004;112:967‐973.
    1. Wang JZ, Cowley A, McLellan BN. Differentiating hand‐foot syndrome from tinea in patients receiving chemotherapy. Acta Oncol. 2016;55:1061‐1064.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren